A new twice-yearly injection has the potential to transform how HIV is prevented, yet experts warn that the biggest challenge may not be medical but moral: deciding who gets access. The development, highlighted by Al Jazeera’s Mikail Malik, comes at a time when global health budgets are shrinking and the influence of pharmaceutical companies on drug pricing continues to grow.
While the treatment is being described as the closest thing to an HIV vaccine, its rollout raises urgent questions about the allocation of public money, the power dynamics of the pharmaceutical industry, and the risk that life-saving interventions could become available only to those who can afford them.
As the global community grapples with declining funding for health initiatives, the debate over equitable access to this groundbreaking therapy is set to intensify in the coming months.
Another wonder drug doomed by capitalism? History suggests pharmaceutical companies will prioritize profit over public health access again.
This is huge news! Twice-yearly shots are so much better than daily pills. Excited but worried about cost.
I’m curious how developing nations will negotiate pricing. Will generic manufacturers step in like they did for antiretrovirals?
Medical breakthroughs mean nothing if only the wealthy can afford them. Equity must be central to this rollout.